Related references
Note: Only part of the references are listed.Phenotypic Features of Crohn's Disease Associated With Failure of Medical Treatment
Gordon W. Moran et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2014)
Dose optimization is effective in ulcerative colitis patients losing response to infliximab: A collaborative multicentre retrospective study
Monica Cesarini et al.
DIGESTIVE AND LIVER DISEASE (2014)
Combination Therapy With Infliximab and Azathioprine Is Superior to Monotherapy With Either Agent in Ulcerative Colitis
Remo Panaccione et al.
GASTROENTEROLOGY (2014)
Clinical Efficacy of lnfliximab in Moderate to Severe Ulcerative Colitis in a Latin American Referral Population
Fabian Juliao et al.
DIGESTION (2013)
Infliximab in Steroid-dependent Ulcerative Colitis: Effectiveness and Predictors of Clinical and Endoscopic Remission
Alessandro Armuzzi et al.
INFLAMMATORY BOWEL DISEASES (2013)
Outcomes after escalation of infliximab therapy in ambulatory patients with moderately active ulcerative colitis
E. Rostholder et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2012)
Management of cytomegalovirus infection in inflammatory bowel diseases
Sylvie Pillet et al.
DIGESTIVE AND LIVER DISEASE (2012)
Long-term infliximab maintenance therapy for ulcerative colitis: The ACT-1 and-2 extension studies
Walter Reinisch et al.
INFLAMMATORY BOWEL DISEASES (2012)
Effect and Safety of Granulocyte-Monocyte Adsorption Apheresis for Patients with Ulcerative Colitis Positive for Cytomegalovirus in Comparison with Immunosuppressants
Takuya Yoshino et al.
DIGESTION (2011)
The Utility of Biomarkers in the Diagnosis and Therapy of Inflammatory Bowel Disease
James D. Lewis
GASTROENTEROLOGY (2011)
A Multicenter Experience With Infliximab for Ulcerative Colitis: Outcomes and Predictors of Response, Optimization, Colectomy, and Hospitalization
Abderrahim Oussalah et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2010)
Trough serum infliximab: a predictive factor of clinical outcome for infliximab treatment in acute ulcerative colitis
C. H. Seow et al.
GUT (2010)
Review: Optimal use of biologics in the management of Crohn’s disease
Remo Panaccione et al.
Therapeutic Advances in Gastroenterology (2010)
European evidence-based Consensus on the prevention, diagnosis and management of opportunistic infections in inflammatory bowel disease
J. F. Rahier et al.
JOURNAL OF CROHNS & COLITIS (2009)
Infliximab therapy decreases the levels of TNF- and IFN- mRNA in colonic mucosa of ulcerative colitis
Trine Olsen et al.
SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY (2009)
Cytomegalovirus infection in inflammatory bowel disease patients undergoing anti-TNFα therapy
Valeria D'Ovidio et al.
JOURNAL OF CLINICAL VIROLOGY (2008)
Long-term outcome after infliximab for refractory ulcerative colitis
Marc Ferrante et al.
JOURNAL OF CROHNS & COLITIS (2008)
Infliximab dose intensification in Crohn's disease
Miguel Regueiro et al.
INFLAMMATORY BOWEL DISEASES (2007)
Infliximab in severe ulcerative colitis: short-term results of different infusion regimens and long-term follow-up
A. Kohn et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2007)
Infliximab for induction and maintenance therapy for ulcerative colitis
P Rutgeerts et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Optimizing anti-TNF treatment in inflammatory bowel disease
P Rutgeerts et al.
GASTROENTEROLOGY (2004)
Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial
SB Hanauer et al.
LANCET (2002)
Share Paper
